Developer docs
API playgroundTry for free, no card

Search company profiles

Coologics

Full company profile

uuid0002q5h

Namestring
Coologics
Legal namestring
Coologics
Websiteurl
coologics.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Coologics is a clinical-stage medical device company founded in 2019 and headquartered in Broadview Heights, Ohio (Cleveland metro area). The company is developing Vlisse, a single investigational product consisting of a patented, drug-free intravaginal cooling device designed as a tampon-like device to manage vaginal yeast infections by providing rapid symptom relief and clinical cure without antibiotics or drug-related side effects. The device uses proprietary controlled-cooling technology, with published peer-reviewed pilot study data in human and mouse models demonstrating safety and early potential efficacy.

The business model is pre-revenue and centered on regulatory clearance as the gating milestone. Vlisse is pursuing FDA De Novo Class II clearance in the United States and holds Class I device status with a pending CE Mark in the European Union. Upon clearance, the company intends to commercialize through healthcare provider channels (OB/GYNs, women's health clinics) and pharmacy distribution via prescription, operating a B2B2C model. The company has raised just over $3 million in seed funding (April 2025) led by Prevail Partners and Dream Ventures, with participation from Illini Angels and Ohio State Early Investor Network, earmarked for clinical trial completion, FDA submission, and market release.

Coologics is founder-led by Kim Langdon, MD, a practicing OB/GYN who is both a recurrent sufferer of vaginal infections and a preterm birth survivor, serving as CEO, Founder, and Inventor. Nicole Williams, MD serves as Chief Medical Officer. The company has 1-10 employees and operates in the women's health segment, positioning Vlisse against the antibiotic-resistance problem and the link between untreated vaginal infections and preterm births, citing a $14 billion productivity loss attributable to recurrent vaginal infections annually.

Short descriptiontext

Coologics is a clinical-stage medical device company developing Vlisse, a patented drug-free intravaginal cooling device for treating vaginal yeast infections. The Cleveland-based firm is pursuing FDA De Novo Class II clearance and serves OB/GYNs and women seeking antibiotic-free treatment options.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug-free medical devices, vaginal health devices, intravaginal cooling technology, women's health therapeutics, clinical stage devices
Industry1 code
PRIMARYHLAHACAK
Continuous Temperature & Fever Monitoring (Wearable Thermometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Women's Health Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Pre-revenue clinical-stage company developing Vlisse, a drug-free medical device for vaginal yeast infections. Once FDA cleared, the company will generate revenue through sales of its Class II medical device, likely through healthcare provider and pharmacy distribution channels.

vlisse.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Vlisse
Description

Drug-free investigational device for managing vaginal yeast infections using controlled-cooling technology, pursuing FDA clearance as a De Novo Class II medical device.

vlisse.com
Core offering1 text field

Coologics is developing Vlisse, a single drug-free, tampon-like investigational medical device that uses patented controlled-cooling technology to provide rapid symptom relief and clinical cure for vaginal yeast infections without antibiotics. The device is currently in clinical trials and pursuing FDA De Novo Class II clearance in the U.S. and a CE Mark in the EU, with eventual commercial distribution planned through OB/GYNs, women's health clinics, and pharmacies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Published peer-reviewed pilot study demonstrates early potential to relieve symptoms and provide clinical cure
+1 more record
Product overview1 text field

Coologics offers a single product (Vlisse) - a drug-free investigational medical device using patented controlled-cooling technology for treating vaginal yeast and bacterial infections. The tampon-like device is designed to provide rapid drug-free symptom relief and clinical cure without antibiotic-related side effects. The product is being developed as a De Novo Class II medical device in the US and is classified as a Class I Device in the European Union with CE Mark pending.

Product and service1 record
1Vlisse
CategoryWomen's Health Medical Device
Description

Vlisse is a drug-free, tampon-like investigational medical device that uses patented controlled-cooling technology to provide rapid symptom relief and clinical cure for vaginal yeast infections without antibiotics. It is intended for prescription or clinical use by OB/GYNs and women's health providers, targeting women seeking a non-pharmaceutical alternative to traditional antifungal therapies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage women's health medical device company developing in-office reproductive health solutions, with a comparable pre-commercial regulatory profile and OB/GYN-focused commercialization pathway similar to Coologics' Vlisse.

2Minerva Surgical
TypeDirect peer
Description

Women's health medical device company commercializing devices for gynecological conditions; comparable in targeting the OB/GYN channel and pursuing FDA-cleared device solutions for underserved women's health indications.

TypeBroad incumbent
Description

Large established women's health medical device and diagnostics company serving OB/GYNs and reproductive health markets; comparable as a broad incumbent with overlapping distribution channels and clinician relationships that Vlisse will eventually need to access.

TypeDirect peer
Description

Women's health-focused company developing and commercializing prescription products in OB/GYN; comparable in concentrating on differentiated women's health interventions despite pharma (not device) modality.

TypeBroad incumbent
Description

Major women's health diagnostics and medical device company with deep OB/GYN commercial reach; comparable as a broad incumbent whose scale and clinician relationships shape the competitive backdrop for any women's health device launch.

TypeBroad incumbent
Description

Women's health diagnostics company with hereditary cancer and reproductive health testing; comparable as a broad incumbent working with OB/GYNs to inform clinical decisions across reproductive and gynecologic care.

TypeOthers
Description

Diversified life sciences company with a substantial women's health franchise (contraception, gynecologic therapies); adjacent incumbent with overlapping therapeutic categories and global OB/GYN commercial footprint relevant to Vlisse's eventual market.

TypeBroad incumbent
Description

Global women's health pharmaceutical company spun out of Merck with a portfolio spanning contraception, fertility, and gynecologic conditions; comparable as a broad incumbent addressing the same patient population via alternative therapeutic modalities.

TypeDirect peer
Description

Clinical-stage women's health biopharmaceutical/medical device company advancing novel therapies for women's reproductive and sexual health; comparable in clinical-stage profile and women's-health-only focus.

TypeEmerging player
Description

Early-commercial women's health medical device company (Elitone for stress urinary incontinence); comparable as a small, OB/GYN-adjacent medical device startup pursuing FDA-cleared, drug-free solutions for women's health.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coologics

Women's Health Medical Devicescoologics.com

Coologics is a clinical-stage medical device company developing Vlisse, a patented drug-free intravaginal cooling device for treating vaginal yeast infections. The Cleveland-based firm is pursuing FDA De Novo Class II clearance and serves OB/GYNs and women seeking antibiotic-free treatment options.

What Coologics does

Coologics is a clinical-stage medical device company founded in 2019 and headquartered in Broadview Heights, Ohio (Cleveland metro area). The company is developing Vlisse, a single investigational product consisting of a patented, drug-free intravaginal cooling device designed as a tampon-like device to manage vaginal yeast infections by providing rapid symptom relief and clinical cure without antibiotics or drug-related side effects. The device uses proprietary controlled-cooling technology, with published peer-reviewed pilot study data in human and mouse models demonstrating safety and early potential efficacy.

The business model is pre-revenue and centered on regulatory clearance as the gating milestone. Vlisse is pursuing FDA De Novo Class II clearance in the United States and holds Class I device status with a pending CE Mark in the European Union. Upon clearance, the company intends to commercialize through healthcare provider channels (OB/GYNs, women's health clinics) and pharmacy distribution via prescription, operating a B2B2C model. The company has raised just over $3 million in seed funding (April 2025) led by Prevail Partners and Dream Ventures, with participation from Illini Angels and Ohio State Early Investor Network, earmarked for clinical trial completion, FDA submission, and market release.

Coologics is founder-led by Kim Langdon, MD, a practicing OB/GYN who is both a recurrent sufferer of vaginal infections and a preterm birth survivor, serving as CEO, Founder, and Inventor. Nicole Williams, MD serves as Chief Medical Officer. The company has 1-10 employees and operates in the women's health segment, positioning Vlisse against the antibiotic-resistance problem and the link between untreated vaginal infections and preterm births, citing a $14 billion productivity loss attributable to recurrent vaginal infections annually.

Coologics firmographics

Firmographics
Name
Coologics
Legal name
Coologics
Website
https://coologics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Coologics is a clinical-stage medical device company developing Vlisse, a patented drug-free intravaginal cooling device for treating vaginal yeast infections. The Cleveland-based firm is pursuing FDA De Novo Class II clearance and serves OB/GYNs and women seeking antibiotic-free treatment options.
Ownership category
akta.pro rank

Coologics industry classification

Industry
Product category
Women's Health Medical Devices
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHACAK
Continuous Temperature & Fever Monitoring (Wearable Thermometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Drug-free medical devices
  • Vaginal health devices
  • Intravaginal cooling technology
  • Women's health therapeutics
  • Clinical stage devices

Where Coologics is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Coologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Pre-revenue clinical-stage company developing Vlisse, a drug-free medical device for vaginal yeast infections. Once FDA cleared, the company will generate revenue through sales of its Class II medical device, likely through healthcare provider and pharmacy distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Coologics product offering

Product offering

Core offering

Coologics is developing Vlisse, a single drug-free, tampon-like investigational medical device that uses patented controlled-cooling technology to provide rapid symptom relief and clinical cure for vaginal yeast infections without antibiotics. The device is currently in clinical trials and pursuing FDA De Novo Class II clearance in the U.S. and a CE Mark in the EU, with eventual commercial distribution planned through OB/GYNs, women's health clinics, and pharmacies.

Product overview

Coologics offers a single product (Vlisse) - a drug-free investigational medical device using patented controlled-cooling technology for treating vaginal yeast and bacterial infections. The tampon-like device is designed to provide rapid drug-free symptom relief and clinical cure without antibiotic-related side effects. The product is being developed as a De Novo Class II medical device in the US and is classified as a Class I Device in the European Union with CE Mark pending.

Differentiator

Problem solved

Functional benefit

Brands

  • Vlisse: Drug-free investigational device for managing vaginal yeast infections using controlled-cooling technology, pursuing FDA clearance as a De Novo Class II medical device.

Products and services

  • Vlisse Vlisse is a drug-free, tampon-like investigational medical device that uses patented controlled-cooling technology to provide rapid symptom relief and clinical cure for vaginal yeast infections without antibiotics. It is intended for prescription or clinical use by OB/GYNs and women's health providers, targeting women seeking a non-pharmaceutical alternative to traditional antifungal therapies.

Quantifiable outcome

  • Published peer-reviewed pilot study demonstrates early potential to relieve symptoms and provide clinical cure
  • +1 more outcomes

Companies that use Coologics

Customer profile

Segments3 records

Ideal customer profiles3 records

Coologics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Coologics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Coologics competitors and assessment

Company assessment

Direct peers

  • Femasys: Clinical-stage women's health medical device company developing in-office reproductive health solutions, with a comparable pre-commercial regulatory profile and OB/GYN-focused commercialization pathway similar to Coologics' Vlisse.
  • Minerva Surgical: Women's health medical device company commercializing devices for gynecological conditions; comparable in targeting the OB/GYN channel and pursuing FDA-cleared device solutions for underserved women's health indications.
  • TherapeuticsMD: Women's health-focused company developing and commercializing prescription products in OB/GYN; comparable in concentrating on differentiated women's health interventions despite pharma (not device) modality.
  • Daré Bioscience: Clinical-stage women's health biopharmaceutical/medical device company advancing novel therapies for women's reproductive and sexual health; comparable in clinical-stage profile and women's-health-only focus.

Broad incumbents

  • CooperSurgical: Large established women's health medical device and diagnostics company serving OB/GYNs and reproductive health markets; comparable as a broad incumbent with overlapping distribution channels and clinician relationships that Vlisse will eventually need to access.
  • Hologic: Major women's health diagnostics and medical device company with deep OB/GYN commercial reach; comparable as a broad incumbent whose scale and clinician relationships shape the competitive backdrop for any women's health device launch.
  • Myriad Genetics: Women's health diagnostics company with hereditary cancer and reproductive health testing; comparable as a broad incumbent working with OB/GYNs to inform clinical decisions across reproductive and gynecologic care.
  • Organon: Global women's health pharmaceutical company spun out of Merck with a portfolio spanning contraception, fertility, and gynecologic conditions; comparable as a broad incumbent addressing the same patient population via alternative therapeutic modalities.

Others

  • Bayer: Diversified life sciences company with a substantial women's health franchise (contraception, gynecologic therapies); adjacent incumbent with overlapping therapeutic categories and global OB/GYN commercial footprint relevant to Vlisse's eventual market.

Emerging players

  • Elidah: Early-commercial women's health medical device company (Elitone for stress urinary incontinence); comparable as a small, OB/GYN-adjacent medical device startup pursuing FDA-cleared, drug-free solutions for women's health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Coologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coologics leadership team

Management profile

Number of profiles

Profiles2 records

Coologics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coologics

What does Coologics do?

Coologics is developing Vlisse, a single drug-free, tampon-like investigational medical device that uses patented controlled-cooling technology to provide rapid symptom relief and clinical cure for vaginal yeast infections without antibiotics. The device is currently in clinical trials and pursuing FDA De Novo Class II clearance in the U.S. and a CE Mark in the EU, with eventual commercial distribution planned through OB/GYNs, women's health clinics, and pharmacies.

Is Coologics a public or private company?

Coologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Coologics founded?

Coologics was founded in 2019. It employs 1 to 10 people.

Where is Coologics based?

Coologics is headquartered in Cleveland, United States, in the North America region.

How does Coologics make money?

One revenue line is on record: medical Device Sales.

Who are Coologics's main competitors?

Direct peers on record are Femasys, Minerva Surgical, TherapeuticsMD and Daré Bioscience. Broad incumbents are CooperSurgical, Hologic, Myriad Genetics and Organon. Bayer is listed as an others. Elidah is listed as an emerging player.

Does Coologics have an API?

No public API is recorded for Coologics.

What industry is Coologics in?

Coologics's product category is Women's Health Medical Devices. Its primary akta.pro industry code is HLAHACAK, Continuous Temperature & Fever Monitoring (Wearable Thermometry). Its NAICS code is 54171 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
International Business TimesAddressing Antibiotic Resistance in Women’s Health: The Potential of Vlisse™ by COOLOGICSCOOLOGICS developed Vlisse™, a non-drug intravaginal cooling device for yeast and bacterial vaginal infections. The device cools the area to force pathogens into dormancy, alleviate inflammation, and promote lactobacillus growth. Clinical and animal studies show promising results, offering an alternative to antibiotics amid rising resistance.citybizCoologics Raises $3M Seed FundingCoologics, a Cleveland-based clinical-stage medical device company, raised $3M in seed funding led by Prevail and Dream Ventures. The funds will accelerate its clinical trial, FDA submission, and market release of Vlisse, a drug-free cooling device for vaginal infections. The company aims to reduce unnecessary antibiotic use.VC News DailyCoologics Announces $3M Seed Funding RoundCoologics, a clinical-stage medical device company, closed a seed round exceeding $3 million, surpassing its $1.5 million target. The round was led by Prevail and Dream Ventures, with participation from two university alumni groups. The funding supports its initial product, Vlisse.Third NewsCoologics Secures Over $3 Million in Seed Funding for Innovative Women’s Health DeviceCoologics Inc. closed an oversubscribed seed round exceeding $3 million to develop Vlisse, a drug-free intravaginal cooling device for vaginal infections. The funds will support clinical trials and FDA submissions, with market entry anticipated. The company aims to reduce antibiotic overuse.PR NewswireCoologics Announces Oversubscribed Seed Funding RoundCoologics Inc. closed an oversubscribed seed round of over $3 million, exceeding its $1.5 million target. The funding, led by Prevail and Dream Ventures, will accelerate clinical trial completion, FDA submission, and market release of its vaginal infection treatment Vlisse.GlobeNewswireCOOLOGICS Initiates Multi-Center Clinical Trials for VlisseCOOLOGICS began multi-center clinical trials for its device Vlisse to treat uncomplicated vulvovaginal candidiasis. The trials will enroll 69 women, with 55 expected to complete, aiming for FDA clearance. The company hopes the drug-free cooling approach reduces reliance on antifungal medications.